Peter J. Van Veldhuizen

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

Amir Goldkorn, Benjamin Ely, David I. Quinn et al. · Journal of Clinical Oncology · 2014 · 329 citations · Full text

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

Matthew R. Smith, Fred Saad, Stéphane Oudard et al. · Journal of Clinical Oncology · 2013 · 247 citations · Full text

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

Tanya B. Dorff, Bryan Goldman, Jacek Pinski et al. · Clinical Cancer Research · 2010 · 209 citations · Full text

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

David I. Quinn, Catherine M. Tangen, Maha Hussain et al. · The Lancet Oncology · 2013 · 159 citations

Urology, Genitourinary Cancer, Medicine +9